Dear Editor,
============

The carbapenemas production is the main mechanisms of resistance to carbapenem antibiotics in Ggram-negative bacilli ([@B1]). In recent years, prevalence of *Klebsiella pneumoniae* Carbapenemase (Bla~KPC~) or KPC phenotype has been reported in Gram-negative bacteria isolated from Iranian patients using the Modified Hodge Test (MHT)([@B2]--[@B8]). According to CLSI (Clinical Laboratory Standards Institute) and CDC (Centers for Disease Control and Prevention) guideline, MHT is being used for detection of carbapenemases in *Enterobacteriaceae* family and not Bla~KPC~ or KPC phenotype ([@B9]--[@B11]). Other carbapenemase such as Metallo-Beta-Lactamase (Bla~NDM~, Bla~VIM~ and Bla~IMP~), Class A of carbapenemases (Bla~SME-1~) and OXA type of carbapenemases can also produce a positive results in MHT method ([@B9]--[@B12]). It should be noted, in some countries such as USA, the most common carbapenemase found in *Enterobacteriaceae* is Bla~KPC~. Therefore this test has a high sensitivity for detection of Bla~KPC~ in this country ([@B10],[@B11]), but in other countries, such as Greece, the most common carbapenemase found in *Enterobacteriaceae* is Bla~VIM~, so, the Bla~VIM~ produce a positive MHT in this country ([@B12]). Considering the facts mentioned, these reports of Iran([@B2]--[@B8]) cannot specify the presence of KPC enzymes in the isolates obtained from Iranian patients and the MHT test does not have a high sensitivity for Bla~KPC~ identification in Iran and other countries unless it is confirmed by molecular methods. The Gram-negative bacilli such as *Enterobacteriaceae*, *Pseudomonas aeruginosa* and *Acinetobacter baumannii* are the most important bacteria in nosocomial infection ([@B13]). To date, these bacteria are almost multidrug resistant (MDR) and show an outstanding ability to rapidly evolve resistance to newer antibiotics ([@B14]). For these isolates, therapeutic options are limited to antibacterial agents such as carbapenems ([@B15]), for these reasons, the accurate detection of carbapenemase-producing isolates is the first critical step in limiting and controlling the spread of the carbapenem of resistant isolates and report of a new mechanism of resistance to antibiotic cause a serious problem on the therapeutic choices existing for treatment of infections ([@B12], [@B16]). Therefore, attempts to reduce spread of antibiotic resistance are based on a detailed knowledge of the mechanisms of resistance ([@B16]).
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